Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class I drug recalls - the high-risk category

Class I is the FDA's most serious recall category: a reasonable probability that using the product will cause serious health consequences or death. It is a small share of all recalls, but the one to check first if a medication you take appears here.

1,750 recalls, newest first.

Class I · High risk

Umovy Acido Hialuronico

Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.

Completed Chemical / undeclared Umary-USA.com D-0493-2025
Class I · High risk

Unavy Acido Hialuronico

Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone, Diclofenac and Omeprazole.

Completed Chemical / undeclared Umary-USA.com D-0492-2025
Class I · High risk

Endurance Boost With Horny Goat Weed

Marketed without approved NDA/ANDA: The product has been found to be tainted with Sildenafil and Propoxyphenylsildenafil (a sildenafil analogue).

Ongoing Chemical / undeclared EnShiShiXiangNiShangMaoYouXianGongSi D-0453-2025
Class I · High risk

Male Ultra Pro

Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.

Ongoing Chemical / undeclared Saini Trade INC D-0467-2025
Class I · High risk

Ultra Armor

Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.

Ongoing Chemical / undeclared Saini Trade INC D-0466-2025
Class I · High risk

Electro Buzz

Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared chloropretadalafil, propoxyphenylsildenafil, and sildenafil.

Ongoing Chemical / undeclared Saini Trade INC D-0465-2025
Class I · High risk

Malextra

Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.

Ongoing Chemical / undeclared Saini Trade INC D-0464-2025
Class I · High risk

Male Ultra

Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.

Ongoing Chemical / undeclared Saini Trade INC D-0463-2025
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class I · High risk

Vitality

Marketed without an approved NDA/ANDA: Product found to be tainted with undeclared sildenafil and tadalafil.

Ongoing Chemical / undeclared One Source Nutrition, Inc, D-0281-2025
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength. Overwrap labeled as Potassium Chloride Inj 10 mEq may contain flexible containers of Potassium Chloride Inj 20 mEq

Ongoing Labeling / mix-up ICU Medical, Inc. NDC 0990-7074-26 D-0268-2025
Class I · High risk

POTASSIUM CHLORIDE Inj.

Labeling: Label Error on Declared Strength. Cases labeled POTASSIUM CHLORIDE 20 mEq, may contain flexible containers with overwrap mislabeled as 10 mEq. The correct dosage strength of 20 mEq is printed on the labeling affixed to the product flexible container.

Ongoing Labeling / mix-up ICU Medical, Inc. NDC 0990-7075-26 D-0267-2025
Class I · High risk

Fentanyl Transdermal System CII

Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.

Ongoing Packaging defect Alvogen, Inc NDC 47781-424-47 D-0245-2025
Class I · High risk

Prograf (tacrolimus)

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk

Astagraf XL

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Ongoing Failed specification Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025

Recalls by year